Wakefulness-promoting agent prescribed for narcolepsy, shift work sleep disorder, and obstructive sleep apnea. Research has explored its effects on cognitive function, sustained attention, and executive performance.
Modafinil 200mg is a wakefulness promoter with low abuse potential, working through dopamine reuptake inhibition and orexin/histamine system activation. Standard dosing is 100–200mg daily, taken 6–8 hours before desired sleep; cycling (5 days on, 2 days off) prevents tolerance. Best taken with food for optimal absorption.
| Use Case | Dose | Timing | Cycling |
|---|---|---|---|
| Cognitive performance | 100–200mg | 7–8 AM with food | 5 days on, 2 days off |
| Shift work adaptation | 100–200mg | 1–2 hours before shift start | Per shift (avoid daily |
| Fatigue management | 100–200mg | 8–9 AM, repeat 12 PM if needed | 5 days on, 2 days off |
| Monitoring | N/A | No labs required for healthy adults | Check HR/BP if cardiovascular risk |
Modafinil's mechanism of action is distinct from traditional stimulants. Rather than flooding the brain with dopamine like amphetamines, it works through a more nuanced pathway that promotes wakefulness without the jitteriness or crash.
Modafinil is a racemic compound. The R-enantiomer (armodafinil) has a longer half-life and is primarily responsible for the extended duration of action. Understanding these parameters helps optimize dosing timing.
| Bioavailability | ~80% (oral) |
| Tmax (time to peak) | 2–4 hours |
| Cmax (200mg dose) | ~4.6 µg/mL |
| Elimination half-life | 12–15 hours (R-enantiomer: ~15h, S-enantiomer: ~4h) |
| Steady state | 2–4 days |
| Volume of distribution | ~0.9 L/kg |
| Protein binding | ~62% (primarily albumin) |
| Metabolism | Hepatic — CYP3A4/5 (primary), CYP2C19. Moderate CYP3A4 inducer. |
| Active metabolite | Modafinil acid (inactive), modafinil sulfone (weakly active) |
| Excretion | Renal (~80%), <10% excreted unchanged |
| Food effect | Delays Tmax by ~1 hour. No significant effect on overall absorption (AUC). |
Your prescribing physician will determine the final dosing schedule. These are evidence-based guidelines commonly used in clinical practice and biohacking protocols.
Modafinil is one of the most-studied cognitive enhancers in existence. Below are key studies relevant to off-label cognitive use in healthy individuals.
Modafinil's safety profile is well-established from over two decades of clinical use. Incidence rates below are from controlled clinical trials at the 200mg dose.
Modafinil is a moderate inducer of CYP3A4 and an inhibitor of CYP2C19. This affects the metabolism of several commonly used drugs. Your prescribing physician will review your full medication list.
Your ₹1,799/month isn't just medication. It's a physician-supervised protocol with everything you need to optimize safely.
Book a consultation with a licensed physician to discuss whether modafinil is appropriate for you.